UBS Group AG Has $12.29 Million Position in Inventiva S.A. Sponsored ADR $IVA

UBS Group AG lifted its holdings in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 28,881.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,643,702 shares of the company’s stock after purchasing an additional 2,634,580 shares during the period. UBS Group AG’s holdings in Inventiva were worth $12,293,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IVA. Creative Planning bought a new position in shares of Inventiva in the second quarter valued at about $32,000. NewEdge Advisors LLC bought a new stake in Inventiva during the 3rd quarter worth about $116,000. Wealth Enhancement Advisory Services LLC grew its holdings in Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after acquiring an additional 9,212 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in Inventiva in the 3rd quarter valued at about $649,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Stock Up 0.2%

Shares of NASDAQ IVA opened at $5.55 on Friday. Inventiva S.A. Sponsored ADR has a 1 year low of $2.85 and a 1 year high of $7.98. The firm’s 50-day moving average is $5.66 and its 200-day moving average is $5.34.

Inventiva (NASDAQ:IVA) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. As a group, analysts predict that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on IVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Truist Financial began coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. Barclays began coverage on shares of Inventiva in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price objective for the company. HC Wainwright set a $24.00 price objective on Inventiva and gave the stock a “buy” rating in a report on Wednesday, January 28th. Finally, Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.